分化型甲状腺癌患者接受仑伐替尼治疗的长期临床结局:日本真实世界实践结果
日本国家癌症中心东医院回顾性队列研究纳入2011至2022年接受仑伐替尼治疗的91例分化型甲状腺癌患者,采用24 mg/日起始剂量、按不良事件调整计划性停药、剂量递增及局部治疗等管理策略。中位观察2.9年,最佳总体缓解率60.4%,中位无进展生存期2.4年(95%CI 1.9-3.3),中位总生存期5.1年(95%CI 3.3-6.7)。
要点
- 91例分化型甲状腺癌患者中,乳头状癌59例(64.8%),滤泡状癌22例(24.2%)。
- 最佳总体缓解率为60.4%,部分缓解55例,完全缓解0例。
- 中位无进展生存期2.4年(95%CI 1.9-3.3),中位总生存期5.1年(95%CI 3.3-6.7)。
核心结论
- 在放射性碘难治性分化型甲状腺癌患者中,谨慎的治疗优化和不良事件管理有助于获得良好且持久的预后。
研究设计与样本
- 回顾性队列研究,纳入2011至2022年在日本国家癌症中心东医院接受仑伐替尼治疗的分化型甲状腺癌患者91例;部分患者曾入组前瞻性临床试验(NCT01321554和UMIN000022243)。
主要发现
- 91例患者中乳头状癌59例(64.8%),滤泡状癌22例(24.2%);最佳总体缓解率60.4%(部分缓解55例,完全缓解0例)。
- 中位观察期2.9年(范围0.1-12.4;四分位距1.7-4.6),期间接受计划性停药者72例(79.1%),全身性疾病进展时仑伐替尼剂量递增者21例(23.1%),寡进展性疾病接受局部治疗者11例(12.1%)。
- 中位无进展生存期2.4年(95%CI 1.9-3.3),中位总生存期5.1年(95%CI 3.3-6.7)。
- 数据截止时,19.8%的患者因不良事件停用仑伐替尼,但无5级不良事件。
关键数值与推荐
- 仑伐替尼起始剂量为24 mg/日。
- 根据个体不良事件状态调整用药计划(计划性停药)。
- 全身性疾病进展时进行仑伐替尼剂量递增。
- 疾病进展时如适用则进行局部治疗。
临床怎么用
- 本研究中心对放射性碘难治性分化型甲状腺癌患者采用仑伐替尼24 mg/日起始、按不良事件调整计划性停药、剂量递增及局部治疗等治疗和管理策略。
- 作者认为,谨慎的治疗优化和不良事件管理有助于获得良好且持久的预后。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Although accumulated experience with lenvatinib in patients with differentiated thyroid cancer (DTC) and progressive radioactive iodine (RAI)-refractory disease has been used to improve management strategies for this disease, findings regarding the actual clinical picture and long-term observation data are insufficient. Methods: We conducted a retrospective cohort study of patients with DTC who received lenvatinib treatment from 2011 to 2022 at the National Cancer Center Hospital East, Japan. The patients were treated under the following treatment and management policies (1) starting dose at 24 mg/day, (2) schedule modification according to individual adverse events status (planned drug holidays), (3) dose escalation of lenvatinib, and (4) local therapy at disease progression, if applicable. This is a retrospective cohort study, although some patients were enrolled in a prospective clinical trial (NCT01321554 and UMIN000022243). Results: Of 91 patients, 59 (64.8%) had papillary carcinoma and 22 (24.2%) had follicular carcinoma. Best overall response in all patients was 60.4% (partial response in 55 and complete response in 0). With a median observation period of 2.9 years (range, 0.1-12.4; interquartile range, 1.7-4.6) under supportive management, including the planned drug holidays (n = 72, 79.1%), dose escalation of lenvatinib at systemic disease progression (n = 21, 23.1%), and local therapy for oligoprogressive disease (n = 11, 12.1%), median progression-free survival and overall survival were 2.4 years (95% confidence interval [CI] 1.9-3.3) and 5.1 years (95% CI 3.3-6.7), respectively. At the time of data cutoff, 19.8% had discontinued lenvatinib treatment due to adverse events, although no adverse event was grade 5. Conclusions: In patients with RAI-refractory DTC treated with lenvatinib, careful treatment optimization and management of adverse events contribute to a favorable, durable prognosis.
引用
- Onaga R, Enokida T, Tanaka N, et al. Long-Term Clinical Outcomes of Patients with Differentiated Thyroid Cancer Treated with Lenvatinib: Results from Real-World Practice in Japan. Thyroid. 2025. PMID: 40488639. doi:10.1089/thy.2025.0040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。